Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China
BackgroundThe widespread use of vaccines against the novel coronavirus disease (COVID-19) has become one of the most effective means to establish a population immune barrier. Patients with cancer are vulnerable to COVID-19 infection, adverse events, and high mortality, and sh...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2023-12-01
|
| Series: | JMIR Public Health and Surveillance |
| Online Access: | https://publichealth.jmir.org/2023/1/e46009 |
| _version_ | 1827593332355760128 |
|---|---|
| author | Shaohua Zhang Jianbin Li Ruonan Xu Qianjun Chen Gang Sun Ying Lin Yali Cao Yiding Chen Cuizhi Geng Yuee Teng Jianyun Nie Xinzheng Li Guiying Xu Xinlan Liu Feng Jin Zhimin Fan Ting Luo Hong Liu Fu-sheng Wang Zefei Jiang |
| author_facet | Shaohua Zhang Jianbin Li Ruonan Xu Qianjun Chen Gang Sun Ying Lin Yali Cao Yiding Chen Cuizhi Geng Yuee Teng Jianyun Nie Xinzheng Li Guiying Xu Xinlan Liu Feng Jin Zhimin Fan Ting Luo Hong Liu Fu-sheng Wang Zefei Jiang |
| author_sort | Shaohua Zhang |
| collection | DOAJ |
| description |
BackgroundThe widespread use of vaccines against the novel coronavirus disease (COVID-19) has become one of the most effective means to establish a population immune barrier. Patients with cancer are vulnerable to COVID-19 infection, adverse events, and high mortality, and should be the focus of epidemic prevention and treatment. However, real-world data on the safety of vaccines for patients with breast cancer are still scarce.
ObjectiveThis study aims to compare the safety of COVID-19 vaccines between patients vaccinated before or after being diagnosed with breast cancer.
MethodsPatients with breast cancer who sought medical advice from October 2021 to December 2021 were screened. Those who received COVID-19 vaccines were enrolled in this study to analyze the safety of the vaccines. The primary outcome was patient-reported adverse events (AEs). All events after vaccine injection were retrospectively documented from the patients.
ResultsA total of 15,455 patients with breast cancer from 41 hospitals in 20 provinces in China were screened, and 5766 patients who received COVID-19 vaccines were enrolled. Of those enrolled, 45.1% (n=2599) of patients received vaccines before breast cancer diagnosis, 41.3% (n=2379) were vaccinated after diagnosis, and 13.6% (n=784) did not known the accurate date of vaccination or cancer diagnosis. Among the patients vaccinated after diagnosis, 85.4% (n=2032) were vaccinated 1 year after cancer diagnosis and 95.4% (n=2270) were vaccinated during early-stage cancer. Of all 5766 vaccinated patients, 93.9% (n=5415) received an inactivated vaccine, 3.7% (n=213) received a recombinant subunit vaccine, and 2.4% (n=138) received other vaccines, including adenovirus and mRNA vaccines. In the first injection of vaccines, 24.4% (n=10, 95% CI 11.2-37.5) of patients who received an adenovirus vaccine reported AEs, compared to only 12.5% (n=677, 95% CI 11.6-13.4) of those who received an inactivated vaccine. Patients with metastatic breast cancer reported the highest incidence of AEs (n=18, 16.5%, 95% CI 9.5-23.5). Following the second injection, patients who received an inactivated vaccine (n=464, 8.7%, 95% CI 8.0-9.5) and those who received a recombinant vaccine (n=25, 8.7%, 95% CI 5.5-12.0) reported the same incidence of AEs. No significant differences in patient-reported AEs were found between the healthy population and patients with breast cancer (16.4% vs 16.9%, respectively); the most common AEs were local pain (11.1% vs 9.1%, respectively), fatigue (5.5% vs 6.3%, respectively), and muscle soreness (2.3% vs 3.6%, respectively). The type of vaccine and time window of vaccination had little impact on patient-reported AEs.
ConclusionsCompared with patients vaccinated before breast cancer diagnosis, there were no significant differences in patient-reported AEs in the patients vaccinated after diagnosis. Thus, it is safe for patients with breast cancer, especially for those in the early stage, to receive COVID-19 vaccines.
Trial RegistrationChinese Clinical Trial Registry ChiCTR2200055509; https://tinyurl.com/33zzj882 |
| first_indexed | 2024-03-09T02:09:00Z |
| format | Article |
| id | doaj.art-9e57c0e08abc43498abddf317780bc82 |
| institution | Directory Open Access Journal |
| issn | 2369-2960 |
| language | English |
| last_indexed | 2024-03-09T02:09:00Z |
| publishDate | 2023-12-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR Public Health and Surveillance |
| spelling | doaj.art-9e57c0e08abc43498abddf317780bc822023-12-07T15:15:40ZengJMIR PublicationsJMIR Public Health and Surveillance2369-29602023-12-019e4600910.2196/46009Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in ChinaShaohua Zhanghttps://orcid.org/0000-0002-3911-2398Jianbin Lihttps://orcid.org/0000-0001-7813-0452Ruonan Xuhttps://orcid.org/0000-0002-4180-7754Qianjun Chenhttps://orcid.org/0000-0001-6761-7740Gang Sunhttps://orcid.org/0000-0002-7804-1967Ying Linhttps://orcid.org/0000-0002-5923-3306Yali Caohttps://orcid.org/0009-0008-6465-2880Yiding Chenhttps://orcid.org/0000-0002-2263-6275Cuizhi Genghttps://orcid.org/0000-0001-5541-5412Yuee Tenghttps://orcid.org/0000-0002-9198-9795Jianyun Niehttps://orcid.org/0000-0003-3691-8940Xinzheng Lihttps://orcid.org/0000-0002-5409-0860Guiying Xuhttps://orcid.org/0000-0003-0526-7401Xinlan Liuhttps://orcid.org/0009-0004-6798-7628Feng Jinhttps://orcid.org/0000-0002-0325-5362Zhimin Fanhttps://orcid.org/0000-0001-5236-7814Ting Luohttps://orcid.org/0000-0002-9670-4031Hong Liuhttps://orcid.org/0000-0002-3985-9504Fu-sheng Wanghttps://orcid.org/0000-0002-8043-6685Zefei Jianghttps://orcid.org/0000-0002-4295-0173 BackgroundThe widespread use of vaccines against the novel coronavirus disease (COVID-19) has become one of the most effective means to establish a population immune barrier. Patients with cancer are vulnerable to COVID-19 infection, adverse events, and high mortality, and should be the focus of epidemic prevention and treatment. However, real-world data on the safety of vaccines for patients with breast cancer are still scarce. ObjectiveThis study aims to compare the safety of COVID-19 vaccines between patients vaccinated before or after being diagnosed with breast cancer. MethodsPatients with breast cancer who sought medical advice from October 2021 to December 2021 were screened. Those who received COVID-19 vaccines were enrolled in this study to analyze the safety of the vaccines. The primary outcome was patient-reported adverse events (AEs). All events after vaccine injection were retrospectively documented from the patients. ResultsA total of 15,455 patients with breast cancer from 41 hospitals in 20 provinces in China were screened, and 5766 patients who received COVID-19 vaccines were enrolled. Of those enrolled, 45.1% (n=2599) of patients received vaccines before breast cancer diagnosis, 41.3% (n=2379) were vaccinated after diagnosis, and 13.6% (n=784) did not known the accurate date of vaccination or cancer diagnosis. Among the patients vaccinated after diagnosis, 85.4% (n=2032) were vaccinated 1 year after cancer diagnosis and 95.4% (n=2270) were vaccinated during early-stage cancer. Of all 5766 vaccinated patients, 93.9% (n=5415) received an inactivated vaccine, 3.7% (n=213) received a recombinant subunit vaccine, and 2.4% (n=138) received other vaccines, including adenovirus and mRNA vaccines. In the first injection of vaccines, 24.4% (n=10, 95% CI 11.2-37.5) of patients who received an adenovirus vaccine reported AEs, compared to only 12.5% (n=677, 95% CI 11.6-13.4) of those who received an inactivated vaccine. Patients with metastatic breast cancer reported the highest incidence of AEs (n=18, 16.5%, 95% CI 9.5-23.5). Following the second injection, patients who received an inactivated vaccine (n=464, 8.7%, 95% CI 8.0-9.5) and those who received a recombinant vaccine (n=25, 8.7%, 95% CI 5.5-12.0) reported the same incidence of AEs. No significant differences in patient-reported AEs were found between the healthy population and patients with breast cancer (16.4% vs 16.9%, respectively); the most common AEs were local pain (11.1% vs 9.1%, respectively), fatigue (5.5% vs 6.3%, respectively), and muscle soreness (2.3% vs 3.6%, respectively). The type of vaccine and time window of vaccination had little impact on patient-reported AEs. ConclusionsCompared with patients vaccinated before breast cancer diagnosis, there were no significant differences in patient-reported AEs in the patients vaccinated after diagnosis. Thus, it is safe for patients with breast cancer, especially for those in the early stage, to receive COVID-19 vaccines. Trial RegistrationChinese Clinical Trial Registry ChiCTR2200055509; https://tinyurl.com/33zzj882https://publichealth.jmir.org/2023/1/e46009 |
| spellingShingle | Shaohua Zhang Jianbin Li Ruonan Xu Qianjun Chen Gang Sun Ying Lin Yali Cao Yiding Chen Cuizhi Geng Yuee Teng Jianyun Nie Xinzheng Li Guiying Xu Xinlan Liu Feng Jin Zhimin Fan Ting Luo Hong Liu Fu-sheng Wang Zefei Jiang Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China JMIR Public Health and Surveillance |
| title | Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China |
| title_full | Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China |
| title_fullStr | Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China |
| title_full_unstemmed | Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China |
| title_short | Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China |
| title_sort | safety of covid 19 vaccination in patients with breast cancer cross sectional study in china |
| url | https://publichealth.jmir.org/2023/1/e46009 |
| work_keys_str_mv | AT shaohuazhang safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT jianbinli safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT ruonanxu safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT qianjunchen safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT gangsun safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT yinglin safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT yalicao safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT yidingchen safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT cuizhigeng safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT yueeteng safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT jianyunnie safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT xinzhengli safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT guiyingxu safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT xinlanliu safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT fengjin safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT zhiminfan safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT tingluo safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT hongliu safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT fushengwang safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina AT zefeijiang safetyofcovid19vaccinationinpatientswithbreastcancercrosssectionalstudyinchina |